@article{PagottoSimeoneBroccoetal.2023,
  author    = {Pagotto, Sara and Simeone, Pasquale and Brocco, Davide and Catitti, Giulia and De Bellis, Domenico and Vespa, Simone and Di Pietro, Natalia and Marinelli, Lisa and Di Stefano, Antonio and Veschi, Serena and De Lellis, Laura and Verginelli, Fabio and Kaitsas, Francesco and Iezzi, Manuela and Pandolfi, Assunta and Visone, Rosa and Tinari, Nicola and Caruana, Ignazio and Di Ianni, Mauro and Cama, Alessandro and Lanuti, Paola and Florio, Rosalba},
  title     = {CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy},
  series = {Cancers},
  volume    = {15},
  journal   = {Cancers},
  number    = {4},
  issn      = {2072-6694},
  doi       = {10.3390/cancers15041052},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304195},
  year      = {2023},
  abstract  = {Extracellular vesicles (EVs) are a heterogenous population of plasma membrane-surrounded particles that are released in the extracellular milieu by almost all types of living cells. EVs are key players in intercellular crosstalk, both locally and systemically, given that they deliver their cargoes (consisting of proteins, lipids, mRNAs, miRNAs, and DNA fragments) to target cells, crossing biological barriers. Those mechanisms further trigger a wide range of biological responses. Interestingly, EV phenotypes and cargoes and, therefore, their functions, stem from their specific parental cells. For these reasons, EVs have been proposed as promising candidates for EV-based, cell-free therapies. One of the new frontiers of cell-based immunotherapy for the fight against refractory neoplastic diseases is represented by genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes, which in recent years have demonstrated their effectiveness by reaching commercialization and clinical application for some neoplastic diseases. CAR-T-derived EVs represent a recent promising development of CAR-T immunotherapy approaches. This crosscutting innovative strategy is designed to exploit the advantages of genetically engineered cell-based immunotherapy together with those of cell-free EVs, which in principle might be safer and more efficient in crossing biological and tumor-associated barriers. In this review, we underlined the potential of CAR-T-derived EVs as therapeutic agents in tumors.},
  language  = {en}
}